Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The COVID Moonshot, a non-profit, open-science consortium of scientists from around the world dedicated to the discovery of globally affordable and easily-manufactured antiviral drugs against COVID-19 and future viral pandemics has received key funding of £8 million from the Wellcome Trust, on behalf of the Covid-19 Therapeutics Accelerator.

Test tube, petri dishes and an oral medication tablet

'Faced with global vaccine inequality and the rapid spread of variants of concern, the need for easily-accessible antiviral therapeutics to treat people with COVID-19 is as pressing as ever, especially in low- and middle-income countries,' said Annette von Delft, Translational Scientist at the University of Oxford and NIHR Oxford Biomedical Research Centre (BRC).

'Most of the research and funding efforts early in the pandemic focused predominantly on repurposing of existing small molecule drugs and the more rapid development of novel monoclonal antibodies. Now, with the realization that COVID-19 will be a global issue for the foreseeable future we urgently need to develop novel antiviral therapeutics. We are therefore thrilled to receive this critical funding from Wellcome and hope it can lead to more support,' said Alpha Lee, Chief Scientific Officer at PostEra and Faculty Member at the University of Cambridge.

The Moonshot started as a spontaneous virtual collaboration in March 2020. As countries locked down, a group of scientists, academics, pharmaceutical research teams and students began a worldwide, twitter-fuelled race against the clock to identify new molecules that could block SARS-CoV-2 infection and develop pills that would be readily available to the most vulnerable communities.

Read the full story on the University of Oxford website.

Similar stories

Professor Dame Sarah Gilbert delivers 44th Dimbleby Lecture

Professor Dame Sarah Gilbert, Saïd Professorship of Vaccinology, Jenner Institute & Nuffield Department of Clinical Medicine, delivered the 44th Richard Dimbleby Lecture, named after the late broadcaster, Richard Dimbleby.

Com-COV2 study supports flexible second dose options following Pfizer or Oxford/AstraZeneca jabs

Following up first doses of the Oxford-AstraZeneca or Pfizer-BioNTech vaccines with second doses of the Moderna or Novavax jabs will generate robust immune responses against COVID-19, according to researchers running the University of Oxford-led Com-COV study.

Meta must do better - data from social media giant essential to mental health research

People are rightly sceptical about scientific discoveries made in secret or without scrutiny. And anyone claiming to have found a new planet with a toy telescope, would not be taken seriously. Recent leaks of internal Facebook research on the mental health of children and young people have caused a great stir on both sides of the Atlantic.

New Oxford-GSK Institute to harness advanced technology and unravel mechanisms of disease

GlaxoSmithKline plc and the University of Oxford today announced a major five-year collaboration to establish the Oxford-GSK Institute of Molecular and Computational Medicine.

Oxford researchers honoured by British Society for Immunology

Four researchers from the University of Oxford have been recognised for their outstanding contributions to immunology with Honorary Lifetime Membership of the British Society for Immunology, with the awards being announced at the recent British Society for Immunology Congress held in Edinburgh.

Medical Sciences researchers scoop 2021 Times Higher Education Awards

Coronavirus researchers from across Medical Sciences have been honoured at the 2021 Times Higher Education (THE) Awards.